Acellular Tissue Engineered Vessel (ATEV)
Phase 3Recruiting 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
End Stage Renal Disease (ESRD)
Conditions
End Stage Renal Disease (ESRD)
Trial Timeline
Sep 7, 2023 → Oct 1, 2027
NCT ID
NCT05908084About Acellular Tissue Engineered Vessel (ATEV)
Acellular Tissue Engineered Vessel (ATEV) is a phase 3 stage product being developed by Humacyte for End Stage Renal Disease (ESRD). The current trial status is recruiting. This product is registered under clinical trial identifier NCT05908084. Target conditions include End Stage Renal Disease (ESRD).
What happened to similar drugs?
20 of 20 similar drugs in End Stage Renal Disease (ESRD) were approved
Approved (20) Terminated (2) Active (0)
✅Henagliflozin 5 mg Group + Henagliflozin 10 mg Group + Conventional therapy groupJiangsu Hengrui MedicineApproved
Hype Score Breakdown
Clinical
17
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07141641 | Pre-clinical | Active |
| NCT05908084 | Phase 3 | Recruiting |
Competing Products
20 competing products in End Stage Renal Disease (ESRD)